Corcept Therapeutics Incorporated (NASDAQ:CORT) bio-pharma drug manufacturer will be discussing 2Q20 financial results with the investment community.on 4th August 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.corcept.com
Earnings Expectation
Corcept Therapeutics Incorporated bio-pharma drug manufacturer, is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020. Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.22 per share. Looking ahead, the full year income are expected at $ 0.89 per share on the revenues of $ 368.27 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 355.00 million ~ $ 375.00 million
Click Here For More Historical Outlooks Of Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushings syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors.
